GlassScriptPhysician profile
Dora Perez
NPI 1467852251
$8,494.85
in general payments reported to CMS, 2019-2025
47 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575 · 2022: $796 · 2023: $169 · 2024: $4,325 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,137 · Travel and Lodging: $1,914 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,137.00 |
| Travel and Lodging | $1,914.41 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,651.98 | 2021-2025 | Infinity, Proclaim |
| Boston Scientific Corporation | $1,557.04 | 2024-2025 | Vercise, General - Dbs |
| Abbvie INC. | $763.23 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $534.43 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $510.50 | 2024-2025 | Briviact, Fintepla, Rystiggo |
| Collegium Pharmaceutical, INC. | $508.68 | 2021-2024 | Belbuca |
| Medtronic, INC. | $348.82 | 2022-2025 | Percept PC Brainsense, Stealthstation S8 Platform |
| Neurelis, INC. | $221.97 | 2024-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $197.52 | 2024-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Servier Pharmaceuticals LLC | $169.49 | 2024-2025 | |
| Tanabe Pharma America, INC. | $165.12 | 2024-2025 | Radicava |
| Neurocrine Biosciences, INC. | $151.62 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $135.70 | 2024-2025 | Vyepti |
| Sk Life Science, INC. | $128.20 | 2024-2025 | |
| Tonix Medicines, INC. | $122.06 | 2024-2025 | Zembrace Symtouch |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dora Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.